NASDAQ:BEAM

Beam Therapeutics Q3 2026 Earnings Results & Report

Beam Therapeutics logo
$20.86 -0.08 (-0.38%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$21.36 +0.50 (+2.42%)
As of 11/20/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Beam Therapeutics missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 3, 2026. The company reported EPS of -$1.28 versus the -$1.17 consensus estimate, while revenue of $307 thousand fell short of the $8.75 million estimate by $8.44 million. Revenue decreased 96.8% year over year.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Beam Therapeutics EPS Results

Actual EPS
-$1.28
Consensus EPS
-$1.17
Beat/Miss
Missed by -$0.11
One Year Ago EPS
-$1.10
EPS Beat Rate
4 of last 8 quarters

Beam Therapeutics Revenue Results

Actual Revenue
$307 thousand
Expected Revenue
$8.75 million
Beat/Miss
Missed by -$8.44 million
YoY Revenue Growth
-96.80%

Beam Therapeutics Q3 2026 Earnings FAQ

Beam Therapeutics (NASDAQ:BEAM) reported earnings of -$1.28 per share for Q3 2026, missing the consensus estimate of -$1.17. The report was announced on Tuesday, November 3, 2026.

Beam Therapeutics reported revenue of $307 thousand for Q3 2026, against a consensus estimate of $8.75 million.

Beam Therapeutics Earnings Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
Beam Therapeutics (NASDAQ:BEAM) Price Target Raised to $33.00
See More Beam Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beam Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beam Therapeutics and other key companies, straight to your email.

About Beam Therapeutics

Beam Therapeutics (NASDAQ:BEAM) is a biotechnology company developing genetic medicines using base editing, a form of gene editing designed to make precise changes to DNA. Its platform includes base-editing technologies and delivery systems intended to address diseases by altering the genetic instructions involved in their development.

The company’s research and development programs include potential treatments for genetic diseases, including sickle cell disease. Its work spans medicines made by editing a patient’s cells outside the body as well as approaches intended to deliver gene editing directly to cells in the body. Beam is a clinical-stage company focused on developing its programs rather than selling approved medicines.

Founded in 2017, Beam is headquartered in Cambridge, Massachusetts. John Evans, a company co-founder, serves as its chief executive officer.

View Beam Therapeutics Profile